Amicus Therapeutics wins EC approval of Opfolda for Pompe disease | Seeking Alpha
Amicus releases phase 3 results in Pompe disease trial
SEC Filing | Amicus Therapeutics
Amicus' Pompe approval portends a showdown with Sanofi
Amicus Therapeutics secures $430M deal with Blackstone for Pompe disease combination treatment. | Pharmtales | Pharma News & Analysis posted on the topic | LinkedIn
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Pompe disease treatment: Amicus' Pompe trial not expected to prove superior to Sanofi's Lumizyme
MHRA marketing authorization granted to Amicus' Pompe disease treatment
FDA OKs Amicus Pompe combo, setting up market battle with Sanofi
Pompe disease: Amicus and Paragon agree to develop gene technologies
Amicus Therapeutics Raising Awareness about Pompe Disease in April
g45154moi001.gif
Pompe Disease Therapeutic Market Report 2022:2028 – Industry Growth Forecasts by Manufacturers, Countries, Type and Application | Amicus Therapeutics, Inc., Valerion Therapeutics, LLC, Sanofi S.A., Oxyrane, - Digital Journal
Amicus therapy shows durable muscle function improvements in Pompe disease patients - STAT
SEC Filing | Amicus Therapeutics
New Pompe disease treatment 'exciting,' Amicus chairman says
Bando: Opportunity to Spotlight Your Research in Pompe Disease
UK approval for Pompe Disease therapy
FDA Clears Amicus Therapeutics' Pompe Disease Treatment
Amicus drug for Pompe disease falls short in key clinical trial
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease | Amicus Therapeutics
